AstraZeneca and Oxford defend Covid vaccine trials after questions raised in the U.S.

Former pharmaceutical executives in the U.S. raised questions this week over the Oxford-straZeneca vaccine candidate,
whose developers calculated its combined results as 70% effective based on phase three trial data released Monday.

“We believe that this product will never be licensed in the U.S.,” one group of critical U.S.-based analysts wrote this week.

An AstraZeneca spokesperson stressed that more data will continue to accumulate
and additional analysis will be conducted on the vaccine and its results.

https://www.cnbc.com/2020/11/26/astrazeneca-oxford-defend-vaccine-trials-after-questions-raised-in-us.html


https://www.cnbc.com/2020/11/26/astrazeneca-oxford-defend-vaccine-trials-after-questions-raised-in-us.html